NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 10 February 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 1 to 5.2.2
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Chris Herring Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Ivan Koychev Items 1 to 6.1.3
11. Dr Soo Fon Lim Present for all items
12. Dr Guy Makin Present for all items
13. Professor David Meads Present for all items
14. Giles Monnickendam Present for all items
15. Malcolm Oswald Present for all items
16. Dr Rebecca Payne Items 5 to 6.1.3
17. Professor Chris Parker Present for all items
18. Carole Pitkeathley Present for all items
19. Baljit Singh Present for all items
20. Professor John Watkins Present for all items
21. Dr Ed Wilson Items 1 to 4.2.2 & 6 to 6.2.2

NICE staff present

Helen Knight, Programme Director Items 6 to 6.2.2

Ross Dent, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Linda Landells, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 6 to 6.2.2

Gavin Kenny, Project Manager Items 1 to 4.2.2

Kate Moore, Project Manager Items 4.1.3 & 5 to 6.2.2

Sally Doss, Health Technology Assessment Adviser Items 6 to 6.2.2

Christian Griffiths, Health Technology Assessment Adviser Items 1 to 4.2.2

Caron Jones, Health Technology Assessment Adviser Items 5 to 5.2.2

Michelle Green, Health Technology Assessment Adviser Items 5 to 5.2.2

Vicky Gillis-Elliot, Health Technology Assessment Analyst Items 1 to 4.2.2

Alan Moore, Health Technology Assessment Analyst Items 1 to 4.2.2

Anne Murray-Cota, Health Technology Assessment Analyst Items 5 to 5.2.2

Anita Sangha, Health Technology Assessment Analyst Items 6 to 6.2.2

Ravinder Claire, Senior Analyst, Science Policy and Research Items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Stephen Duffield, Senior Analyst, Data and Analytics team Items 5 to 5.2.2

Thomas Strong, Technical Adviser, Managed Access Items 1 to 4.2.2

Catrin Austin, Technical Analyst, Methods and Economics Items 1 to 4.2.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Liaison Items 1 to 4.2.2

Stephen Norton, Technical Analyst, Managed Access Items 5 to 5.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 5.2.2

Sarah Bromley, Senior Medical Editor Items 1 to 4.2.2 & 6 to 6.1.3

Olivia Havercroft, Senior Medical Editor Items 5 to 5.2.2

Ella Fitzpatrick, Patient Involvement Advisor, PIP Items 6 to 6.1.3

Mandy Tonkinson, Patient Involvement Advisor, PIP Items 6 to 6.1.3

Maria Pitan, Project Manager, Corporate Office Items 1 to 4.1.3 & 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Items 1 to 4.2.2

Iain Cannell, Administrator, TA Items 6 to 6.2.2

Laura Kelly, Administrator, COT Items 5 to 5.2.2

External assessment group representatives present

Anthony Hatswell, Peninsula Technology Assessment Group (Pen-TAG) Items 1 to 4.1.3

Caroline Farmer, Peninsula Technology Assessment Group (Pen-TAG) Items 1 to 4.1.3

Jeremy Howick, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Thea van Asseelt, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Dwayne Boyers, Aberdeen HTA Group Items 6 to 6.1.3

David Cooper, Aberdeen HTA Group Items 6 to 6.1.3

Professional, patient & NHS England experts present

Dr Richard Baker, Consultant in Renal Medicine, clinical expert nominated by, NHS Blood and Transplant, Items 1 to 4.1.3

Dr Sunil Daga, Consultant Nephrologist, clinical expert nominated by the British Transplantation Society, Items 1 to 4.1.3

Professor Colin Geddes, Consultant Nephrologist and Honorary Clinical Associate, clinical expert nominated by The Renal Association, Items 1 to 4.1.3

Professor Gary McVeigh, Innovative Medicines Fund Clinical lead, NHSE England,

Items 1 to 4.1.3

Ian Wren, Commissioning expert, NHS England, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical lead, NHS England, Items 5 to 6.2.2

Dr Thomas Newsom-Davis, Consultant Medical Oncologist, clinical expert nominated by the British Thoracic Oncology Group, Items 5 to 5.1.3

Professor Sanjay Popat, Consultant Medical Oncologist, clinical expert nominated by Roche Products Ltd, Items 5 to 5.1.3

Kevin Gorman, Patient expert nominated by Action Bladder Cancer UK, Items 6 to 6.1.3

Professor Syed A Hussain, Professor of Medical Oncology, clinical expert nominated by Merck Serono Ltd, Items 6 to 6.1.3

Dr Lydia Makaroff, Patient expert nominated by Fight Bladder Cancer, Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 12 January 2022.

### Appraisal of imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Hansa Biopharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
		+ Nominated clinical expert Dr Richard Baker declared financial interests as he has received honoraria from Hansa to attend advisory boards. It was agreed his declaration would not prevent Dr Baker from providing expert advice to the committee.
		+ Nominated clinical expert Dr Sunil Daga declared financial interests in relation to the following.
* He is an investigator in a clinical trial that is looking at effectiveness of another desensitisation treatment funded by Kidney Research UK (ITOPS).
* He holds honorary position as scientific advisor to Kidney Research Yorkshire, medical advisor to South Asian Health Action charity and honorary secretary at British Association of Physicians of Indian Origin (BAPIO) Institute for Health Research.
* He has published opinion on antibody incompatible kidney transplantation.
	+ - It was agreed that his declarations would not prevent Dr Daga from providing expert advice to the committee.
		- Nominated clinical expert Professor Colin Geddes declared financial interests as he has received unrestricted research grant funding from Retrophin Inc in 2018 to his institution. It was agreed that his declaration would not prevent Professor Geddes from providing expert advice to the committee.
		- No further conflicts were declared for this appraisal.
		1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, all experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10552>

### Appraisal of pralsetinib for RET fusion-positive advanced non-small-cell lung cancer [ID3875]

* 1. Part 1 – Open session
		1. The chair Dr Lindsay Smith welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Roche Products Ltd.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
		+ Committee member Dr Ivan Koychev declared financial interests as he has worked on a collaboration with Roche to develop digital technologies for the detection of cognitive impairment. It was agreed his declaration would not prevent Dr Koychev from participating in discussions on this appraisal.
		+ Committee member Dr Ed Wilson declared financial conflicts as His company has worked with Roche on atezolizumab. As a direct conflict Dr Wilson did not participate in discussions on this appraisal.
		+ Nominated clinical expert Dr Thomas Newsom-Davis declared financial interests in relation to the following.
* He has received consultancy and speaker fees from: Amgen, Bayer, AstraZeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Guardant, Janssen, Merck, MSD, Novartis, Otsuka, Pfizer, Roche, Sanofi, Takeda.
* He Chairs the Independent Data Medical Committee (IDMC) for the AcceleRET and ARROW clinical trials, both of which involve Pralsetinib. Formerly this was for BluePrint Medical, and subsequently for Roche Pharmaceuticals.
	+ - It was agreed that his declarations would not prevent Dr Newsom-Davis from providing expert advice to the committee.
		- Nominated clinical expert Dr Sanjay Popat declared financial interests in relation to the following.
* He is a consultant to: Amgen, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Janssen, Lilly, Merck KgaA, MSD, Novartis, Roche, Takeda, Pfizer, AstraZeneca, Bayer, BeiGene, Incyte, Seattle Genetics, Turning Point Therapeutics, Xcovery.
* He is an advisor to: ALK Positive UK, Lung Cancer Europe, Ruth Strauss.
* He is on the Board of Directors for: Mesothelioma Applied Research Foundation.
* He is on the Leadership Team for: BTOG Steering Committee, and the ETOP Foundation Council.
* He has received institutional research funding from Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, GSK, Guardant Health, Janssen, Lilly, MSD, Novartis, Roche, Takeda, Trizel, Turning Point Therapeutics.
* It was agreed that his declarations would not prevent Dr Popat from providing expert advice to the committee.
* No further conflicts were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Martin Bradley, Professor Rachel Elliott, and Dr Malcolm Oswald.
	1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10770>

### Appraisal of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

* 1. Part 1 – Open session
		1. The chair Dr Lindsay Smith welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Serono Ltd.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated patient expert Kevin Gorman declared indirect financial interests as Action Bladder Cancer UK has received a contribution from Merck and others to help compensate for loss of general income during the coronavirus pandemic. It was agreed this declaration would not prevent Kevin from providing expert advice to the committee.
* Nominated clinical expert Professor Syed A Hussain declared financial interests as he has received research funding from CR UK, MRC/NIHR, UHB charities, CCC charities, Northwest Cancer Research, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre and Eli Lilly and attended advisory boards and received consultancy fees from Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Pierre Fabre, Ipsen and Sotio. It was agreed this declaration would not prevent Professor Hussain from proving expert advice to the committee.
* Nominated patient expert Dr Lydia Makaroff declared indirect financial interests as she is an employee of Fight Bladder Cancer. Fight Bladder Cancer has received financial support from F. Hoffman-La Roche AG, Bristol-Myers Squibb, Janssen Pharmaceutica, Merck KgaA, MSD, and Pfizer, she is also a volunteer board member of the World Bladder Cancer Patient Coalition. The World Bladder Cancer Patient Coalition has received financial support from F. Hoffman-La Roche AG, AstraZeneca, Bayer AG, Astellas Pharma, Bristol-Myers Squibb, Ipsen, Janssen Pharmaceutica, Merck KgaA, MSD, Pfizer, Photocure and SeaGen.
* No further conflicts were declared for this appraisal,
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10624>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 10 March 2022 and will start promptly at 09.30.